Project Overview

A leading global diagnostics company asked us to uncover how Chinese specialists manage four immune-mediated conditions—alopecia areata, hidradenitis suppurativa, systemic sclerosis–associated interstitial lung disease (SSc-ILD) and coeliac disease. Through in-depth virtual interviews with dermatologists, pulmonologists and gastroenterologists, we explored current prescription patterns, perceived gaps and forward-looking preferences that will shape uptake of next-generation therapies. Findings support strategic life-cycle planning for the company’s emerging portfolio.

Key Learning Objectives

• Current Therapy Landscape

  • Quantify the share of JAK inhibitors, biologics and other advanced options in dermatology, respiratory and GI practice.

• Adoption Drivers & Barriers

  • Surface clinical, economic and operational factors that enable—or limit—use of innovative treatments.

• Future Preference Signals

  • Gauge specialists’ likelihood to shift toward newer mechanisms of action over the next few years.

• Portfolio Positioning

  • Identify competitive white spaces and differentiation levers for pipeline assets targeting inflammatory disorders.

Methodology

• Web-Assisted One-on-One Interviews

  • 45–60 minute sessions with six China-based physicians (dermatology × 6, pulmonology × 6, gastroenterology × 6).

  • Semi-structured guide covering patient volumes, treatment sequencing, rationale for therapy choice, and unmet needs.

• Rapid Thematic Analysis

  • Coding and synthesis to map therapy share, forecast switching potential and isolate specialty-specific nuances.

Key Deliverables

• Therapy Share Snapshot outlining current prescription proportions across specialties and diseases.

• Opportunity-Gap Matrix highlighting unmet clinical needs and barriers to novel treatment adoption.

• Strategic Playbook with recommendations on market positioning, indication expansion and promotion lanes to maximise portfolio competitiveness.